Literature DB >> 31945029

Anti-Inflammatory and Antioxidant Effects of Acetyl-L-Carnitine on Atherosclerotic Rats.

Shixun Wang1, Jingtao Xu1, Jiahui Zheng1, Xincai Zhang1, Jingbo Shao1, Luyan Zhao2, Junqiang Hao2.   

Abstract

BACKGROUND The purpose of the present study was to evaluate the regulatory effects of acetyl-L-carnitine (ALCAR) on atherosclerosis in Wister rats and to explore its anti-atherosclerotic mechanism. MATERIAL AND METHODS We randomly divided 32 Wister rats into 4 groups: a normal diet group (control group, n=8), a normal diet+ALCAR group (ALCAR group, n=8), an atherosclerosis group (AS group, n=8), and an atherosclerosis+ALCAR group (AS+ALCAR group, n=8). The serum lipid distribution, oxidative stress, inflammatory factors and adiponectin (APN) in the blood, and heart and aortic tissues were determined using the standard assay kits, xanthine oxidase method, and ELISA, respectively. HE staining was performed to observe aortic pathology structure change, and the level of angiotensin II (AngII) in the aorta was assessed using radioimmunoassay. In addition, real-time quantitative PCR and Western blot analysis were applied to detect the expression of iNOS, IL-1ß, TNF-alpha, and CRP in the aortic and heart tissues. RESULTS Compared with the AS group, the levels of serum TC, TG, LDL, and VLDL in rats decreased significantly, while HDL level significantly increased in the AS+ALCAR group. ALCAR administration enhanced the SOD and GSH-Px activities and decreased MDA activity. APN level was significantly elevated in the AS group, but ALCAR had no significant effect on APN. Further, ALCAR reduced the expressions of inflammation factors TNF-alpha, IL-1ß, iNOS, and CRP, and the concentration of AngII in serum, aortic, and heart tissues. CONCLUSIONS ALCAR can inhibit the expressions of inflammatory factors and antioxidation to suppress the development of atherosclerosis by adjusting blood lipid in the myocardium of AS rats.

Entities:  

Year:  2020        PMID: 31945029     DOI: 10.12659/MSM.920250

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

1.  L-Carnitine protects against tacrolimus-induced renal injury by attenuating programmed cell death via PI3K/AKT/PTEN signaling.

Authors:  Hai-Lan Zheng; Hai-Yue Zhang; Chun-Lian Zhu; Hui-Ying Li; Sheng Cui; Jian Jin; Shang-Guo Piao; Yu-Ji Jiang; Mei-Ying Xuan; Ji-Zhe Jin; Ying-Shun Jin; Jung-Pyo Lee; Byung-Ha Chung; Bum-Soon Choi; Chul-Woo Yang; Can Li
Journal:  Acta Pharmacol Sin       Date:  2020-06-17       Impact factor: 6.150

2.  Carnitine and COVID-19 Susceptibility and Severity: A Mendelian Randomization Study.

Authors:  Chunyu Li; Ruwei Ou; Qianqian Wei; Huifang Shang
Journal:  Front Nutr       Date:  2021-11-25

3.  Baseline microbiome and metabolome are associated with response to ITIS diet in an exploratory trial in patients with rheumatoid arthritis.

Authors:  Roxana Coras; Cameron Martino; Julia M Gauglitz; Francesca Cedola; Anupriya Tripathi; Alan K Jarmusch; Maram Alharthi; Marta Fernandez-Bustamante; Meritxell Agustin-Perez; Abha Singh; Soo-In Choi; Tania Rivera; Katherine Nguyen; Tatyana Shekhtman; Tiffany Holt; Susan Lee; Shahrokh Golshan; Pieter C Dorrestein; Rob Knight; Monica Guma
Journal:  Clin Transl Med       Date:  2022-07

Review 4.  Mini-Review: Mitochondrial dysfunction and chemotherapy-induced neuropathic pain.

Authors:  Timothy M Doyle; Daniela Salvemini
Journal:  Neurosci Lett       Date:  2021-06-26       Impact factor: 3.197

Review 5.  The Nutraceutical Value of Carnitine and Its Use in Dietary Supplements.

Authors:  Alessandra Durazzo; Massimo Lucarini; Amirhossein Nazhand; Selma B Souto; Amélia M Silva; Patrícia Severino; Eliana B Souto; Antonello Santini
Journal:  Molecules       Date:  2020-05-01       Impact factor: 4.411

6.  Treatment repurposing for inflammatory bowel disease using literature-related discovery and innovation.

Authors:  Ronald Neil Kostoff; Michael Brandon Briggs; Darla Roye Shores
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.